ALSA Ventures is a London-based international life science investor focused on novel therapeutics. They believe that European innovation in life sciences has the power to create valuable businesses with global impact, coupled with a promising investment market opportunity in Europe. The firm is focused on being a Europe-focused biotechnology fund manager. Their investment approach centers around therapeutics, seeking novel drugs and modalities across a wide variety of disease areas. ALSA Ventures invests across the entire spectrum of drug development, demonstrating comfort in both company formation and participating in syndicates alongside co-investors. The firm aims to build ambitious science-led companies and NewCos around differentiated assets, requiring a wide aperture for talent and ideas, disciplined decision-making, and an ecosystem that allocates capital efficiently. This aligns with their decision to join the Investing in Women Code, which encourages measurable improvements in access to finance and strengthens data-driven accountability across the investment landscape. ALSA Ventures aims to make their engagement with founders consistent, professional, and transparent, which involves clear routes to initial evaluation and feedback, disciplined processes designed to reduce avoidable friction, and a commitment to ongoing review of how their practices affect access to capital.
Preferred startup development maturity for initial funding deployment.
Novel therapeutics, biotechnology, life sciences, drug development
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...